Abstract
Loss of cardiac function following myocardial infarction (MI) remains a leading cause of morbidity in the developed world. Current percutaneous coronary intervention (PCI) practice facilitates rapid relief of acute thrombotic occlusion with follow on medical treatment of associated atherosclerotic and thrombotic risks, late ventricular remodeling and cardiac arrhythmias. The application of regenerative therapies aimed at preserving or restoring lost myocardial function post large MI is currently evolving. In the early phase of myocardial reperfusion post PCI, cardiomyocyte apoptosis occurs followed closely by pro-inflammatory cell infiltration from the circulation. At later timepoints, matrix protein deposition and scar formation become evident followed by later loss of functioning cardiomyocyte cell mass leading to a dilated failing heart. In the last decade, clinical trials have assessed the ability of therapy using progenitor cells from various tissue niches to prevent or reverse these effects in the post-reperfusion phase. Modest improvements in hemodynamic function reported in many (but not all) of these trials have tempered initial optimism for cardiac regenerative therapeutics. In addition, several issues concerning cardiac cell therapy including efficacy, quality assurance, necessary infrastructure, effective translation of preclinical studies and applicability to broader patient care, have been raised. Fortunately, a number of promising derivative therapeutic strategies have also emerged including stem cell derived paracrine factors and recent advances in tissue engineering. In this review, the ability of stem cells and/or derivative therapies to modify apoptosis and inflammation in the ischemic zone are considered along with emerging cell and tissue engineering approaches toward cardiac regeneration post-MI.
Keywords: Cardiac regeneration, stem cells, paracrine, tissue engineering.
Current Pharmaceutical Design
Title:Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Volume: 20 Issue: 12
Author(s): Kenneth Martin, Chien-Ling Huang and Noel M. Caplice
Affiliation:
Keywords: Cardiac regeneration, stem cells, paracrine, tissue engineering.
Abstract: Loss of cardiac function following myocardial infarction (MI) remains a leading cause of morbidity in the developed world. Current percutaneous coronary intervention (PCI) practice facilitates rapid relief of acute thrombotic occlusion with follow on medical treatment of associated atherosclerotic and thrombotic risks, late ventricular remodeling and cardiac arrhythmias. The application of regenerative therapies aimed at preserving or restoring lost myocardial function post large MI is currently evolving. In the early phase of myocardial reperfusion post PCI, cardiomyocyte apoptosis occurs followed closely by pro-inflammatory cell infiltration from the circulation. At later timepoints, matrix protein deposition and scar formation become evident followed by later loss of functioning cardiomyocyte cell mass leading to a dilated failing heart. In the last decade, clinical trials have assessed the ability of therapy using progenitor cells from various tissue niches to prevent or reverse these effects in the post-reperfusion phase. Modest improvements in hemodynamic function reported in many (but not all) of these trials have tempered initial optimism for cardiac regenerative therapeutics. In addition, several issues concerning cardiac cell therapy including efficacy, quality assurance, necessary infrastructure, effective translation of preclinical studies and applicability to broader patient care, have been raised. Fortunately, a number of promising derivative therapeutic strategies have also emerged including stem cell derived paracrine factors and recent advances in tissue engineering. In this review, the ability of stem cells and/or derivative therapies to modify apoptosis and inflammation in the ischemic zone are considered along with emerging cell and tissue engineering approaches toward cardiac regeneration post-MI.
Export Options
About this article
Cite this article as:
Martin Kenneth, Huang Chien-Ling and Caplice M. Noel, Regenerative Approaches to Post-Myocardial Infarction Heart Failure, Current Pharmaceutical Design 2014; 20 (12) . https://dx.doi.org/10.2174/13816128113199990450
DOI https://dx.doi.org/10.2174/13816128113199990450 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones
Anti-Cancer Agents in Medicinal Chemistry Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Current Pharmaceutical Design Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Meet Our Editor
Central Nervous System Agents in Medicinal Chemistry Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Role of Innate Immune System in Inflammation and Cardiac Remodeling After Myocardial Infarction
Current Vascular Pharmacology Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design The Use of Exercise Echocardiography in the Evaluation of Mitral Regurgitation
Current Cardiology Reviews Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology